At the recent scientific meeting to celebrate the 40th anniversary of the Centre d’Immunologie de Marseille-Luminy (#CIML40), Professor Ton Schumacher from the Netherlands Cancer Institute gave an informative presentation on “T cell recognition and tumor resistance in human cancer.”

Professor Ton Schumacher at CIML40

Picture Credit: ATGC Partners

Schumacher started his talk at CIML by saying, “I guess by now I should consider myself a cancer immunologist…”

Cancer immunologist ‘wannabes’ should take note of the level of expertise required to be considered one!

Neon Therapeutics LogoHe is one of the co-founders of Neon Therapeutics and a leading researcher into antigen-specific T cell immunity.

Several companies are seeking to develop personalized cancer vaccines against patient-specific neoantigens.

We previously wrote about the approach Neon Therapeutics is following based on expert interviews with the interim CEO Cary Pfeffer and scientific co-founder Dr Cathy Wu.

BioNTech LogoYesterday the field heated up when it was announced that German biotech BioNTech AG had entered a strategic collaboration with Genentech to develop individualized mRNA cancer therapies (Sept 20, 2016 press release).

This post continues the BSB mini-series on targeting neoantigens that we started last month. Do check out previous posts if you missed them:

After his #CIML40 presentation, Prof Schumacher kindly spoke to BSB.

Subscribers can login to read more or you can purchase access below.